Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
نویسندگان
چکیده
منابع مشابه
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
BACKGROUND The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that o...
متن کاملthe use of appropriate madm model for ranking the vendors of mci equipments using fuzzy approach
abstract nowadays, the science of decision making has been paid to more attention due to the complexity of the problems of suppliers selection. as known, one of the efficient tools in economic and human resources development is the extension of communication networks in developing countries. so, the proper selection of suppliers of tc equipments is of concern very much. in this study, a ...
15 صفحه اولRituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
Systemic lupus erythematosus (SlE) and autoimmune polyendocrinopathy are characterized by autoantibodies against a variety of target organs. Traditional treatment strategies for immune cytopenias include global immunosuppression that targets both the humoral and cell-mediated arms of the immune system. B-cells play an important role in the pathogenesis of many autoimmune diseases. Targeted depl...
متن کاملautosomal recessive chronic granulomatous disease, iga deficiency and refractory autoimmune thrombocytopenia responding to anti-cd20 monoclonal antibody
immunodeficiency and autoimmune disease may occur concomitantly in the same individual. some of the immunodeficiency syndromes, especially humoral defects are associated with autoimmune disorders. hematological manifestations such as thrombocytopenia and hemolytic anemia are the most common presentations. persistent antigen stimulation due to an inherent defect in the ability of the immune syst...
متن کاملPopulation Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure-response relationships of obinutuzumab still need to be fully described. Data from four clinical trials of obinutuzumab were analyzed to describe th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: eJHaem
سال: 2020
ISSN: 2688-6146,2688-6146
DOI: 10.1002/jha2.78